Beyond Telomere Protection: TRF2 Preserves the Regenerative Identity of Muscle Stem Cells

Skeletal muscle’s ability to rebuild after injury depends not only on stem cells remaining present, but also on their remembering who they are and when to take part in repair. A team at the University of Pennsylvania’s Perelman School of Medicine found that TRF2, a protein previously known for protecting chromosome ends, also preserves the molecular identity of muscle stem cells; the study was published in *Science Advances*.

When muscle is injured, previously dormant stem cells are activated, proliferate, and differentiate to replace damaged tissue; some then return to dormancy, preserving a reservoir of cells needed for the next repair. The researchers observed that TRF2 levels rise and fall as cells transition among dormancy, repair, and self-renewal, indicating that it is not a static component of chromosome protection but may help coordinate the entire regeneration program.

After the team removed TRF2 from muscle stem cells in mice, the muscles initially appeared to have no obvious abnormalities, but the stem cell population gradually declined over time. Contrary to the researchers’ expectations, these cells did not simply die from chromosome damage; instead, they lost the molecular characteristics expected of muscle stem cells. When the muscle was injured, the tissue therefore could not rebuild normally, and fat and scar tissue accumulated instead.

Further mechanistic analysis showed that TRF2 does not remain only at telomeres; it also binds to regulatory regions distributed throughout the genome, helping maintain the genes required for muscle stem cell identity. Many of these binding regions contain G-quadruplex structures—distinctive three-dimensional structures formed by guanine-rich DNA. This finding extends TRF2’s role from passively protecting chromosome ends to actively maintaining cell fate at the level of gene regulation.

In a mouse model of Duchenne muscular dystrophy, when muscle stem cells were additionally deprived of TRF2, muscle degeneration worsened and the animals’ survival was shortened. This supports an association between TRF2 and regenerative capacity in disease, but it does not mean that increasing TRF2 can treat patients; the study has not yet shown whether this pathway can be manipulated safely, nor has it clarified whether long-term changes to TRF2 or G-quadruplex structures might disrupt chromosome stability and gene regulation in other tissues.

This work offers a more nuanced perspective: regenerative failure does not necessarily result from the destruction of repair cells, but may also arise as cellular identity gradually becomes unstable. Only if the relevant mechanisms can be reproduced in human muscle stem cells and patient tissues, and ways can be found to regulate them without disrupting telomere function, might TRF2 progress from a disease clue to a testable therapeutic strategy.